SC
ACOR

Saltoro Capital’s Acorda Therapeutics ACOR Stock Holding History

Saltoro Capital’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,570
Closed -$23.9K – 82
2023
Q1 		$23.9K Sell
2,570
-2,871
-53% -$47.7K 0.01% 48
2022
Q4 		$83.4K Hold
5,441
– – 0.07% 35
2022
Q3 		$33K Hold
5,441
– – 0.01% 41
2022
Q2 		$51K Buy
5,441
+4,699
+633% +$83.5K 0.01% 42
2022
Q1 		$24K Hold
742
– – 0.01% 76
2021
Q4 		$35K Buy
+742
New +$51.1K 0.01% 70
2021
Q3 		– Sell
-593
Closed -$57K – 140
2021
Q2 		$57K Buy
+593
New +$51.9K 0.02% 88

Other funds holding ACOR

DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Saltoro Capital's ACOR Position: Q2 2023 in Review

Saltoro Capital sold out of Acorda Therapeutics (ACOR) in Q2 2023, closing a stake of 2,570 shares — an estimated $23.9K sold.

Saltoro Capital first reported a position in ACOR in Q2 2021 and held it in 7 quarters. The position peaked at $83.4K in Q4 2022. 15 funds tracked by Wall St. Rank hold ACOR as of Q2 2023.

  • Saltoro Capital reported no remaining Acorda Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Saltoro Capital sold 2,570 Acorda Therapeutics shares in Q2 2023, an estimated $23.9K.
  • Saltoro Capital first reported a position in Acorda Therapeutics in Q2 2021 and held it in 7 quarters.
  • Saltoro Capital's Acorda Therapeutics position peaked at $83.4K in Q4 2022.
  • 15 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2023.

Based on Saltoro Capital's 13F filing for Q2 2023, filed 9 Aug 2023.